ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "methotrexate (MTX) and anti-TNF therapy"

  • Abstract Number: 1537 • 2019 ACR/ARP Annual Meeting

    Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study

    Stefan Siebert1, Elisa Gremese 2, Paul Bergmans 3, Kurt De Vlam 4, Beatriz Joven-Ibáñez 5, Gkikas Katsifis 6, Tatiana Korotaeva 7, Wim Noël 8, Carlo Selmi 9, Petros Sfikakis 10, Pavel Smirnov 11, Elke Theander 12, Michael Nurmohamed 13, Laure Gossec 14 and Josef Smolen 15, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, 3Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, 4University Hospitals Leuven, Leuven, Belgium, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, 7Nasonova Research Institute of Rheumatology, Moscow, Russia, 8Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, 9Humanitas Research Hospital, University of Milan, Milan, Italy, 10Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 11Biostatistics and Medical Affairs, Janssen, Moscow, Russia, 12Biostatistics and Medical Affairs, Janssen, Solna, Sweden, 13Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, 14Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 15Medical University of Vienna, Vienna, Austria

    Background/Purpose: The additional benefit of methotrexate as a concomitant treatment in PsA has not been fully elucidated. Observational data exist for concomitant methotrexate (MTX) use…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology